Adenine phosphoribosyltransferase deficiency

Signs and symptoms

Adenine phosphoribosyltransferase deficiency commonly manifests as symptoms of the kidneys and urinary tract such as nephrolithiasis, urolithiasis, crystalline nephropathy, hematuria, acute kidney injury, chronic kidney disease, and Urinary tract infections. No extrarenal symptoms have been documented.

Adenine phosphoribosyltransferase deficiency can present at any age. Studies have shown that the age of diagnoses can vary from infancy to over the age of 70. Some individuals with APRT deficiency remain completely asymptomatic and only get diagnosed because of familial screening. In 15% of adult cases present with renal failure requiring renal replacement therapy. In some cases APRT deficiency is first diagnosed after a kidney transplant when complications arise. The first kidney stone episode can occur within the first few months of birth or later in life. In infants APRT deficiency may manifest as reddish brown diaper stains.

Patients with APRT deficiency typically have normal levels of plasma uric acid, gout and hyperuricemia have been reported in heterozygotes with a partial APRT deficiency.

Complications

Dihydroxyadenine crystals precipitate inside the interstitium and renal tubules as well as cause severe kidney damage. Dihydroxyadenine nephropathy can initially present acutely and lead to renal failure within days to weeks. More commonly dihydroxyadenine nephropathy may develop insidiously, causing a progressive decline in kidney function over the span of several years. Dehydration can trigger acute renal failure which causes urine supersaturation, oliguria, and precipitation of dihydroxyadenine.

Causes

Adenine phosphoribosyltransferase deficiency is an autosomal recessive condition which means that two copies of the mutated gene must be present for adenine phosphoribosyltransferase deficiency to develop.

Genetics

The adenine phosphoribosyltransferase (APRT) gene is found on chromosome 16q24, contains five exons, encompasses 2.8 kb of DNA, and has a coding region of 540 bp. Complete APRT deficiency develops in people who carry mutations in both copies of the APRT gene.

There is no evidence that genotype correlates with phenotype and environmental factors or modifiers might be responsible for this heterogeneity.

Mechanism

All tissues express the APRT enzyme, which offers the sole metabolic route for recovering adenine from dietary and polyamine biosynthesis sources. Adenine can only be found in small amounts in blood and urine because APRT catalyzes the conversion of adenine and 5-phosphoribosyl-1-pyrophosphate into inorganic pyrophosphate and 5′-adenosine monophosphate. Adenine is transformed into 8-hydroxyadenine in people without functional APRT, and xanthine dehydrogenase (XDH), formerly known as xanthine oxydase, then further metabolizes this compound to dihydroxyadenine. Due to its high renal clearance, dihydroxyadenine may be secreted tubularly in addition to being filtered. Thus, APRT deficiency causes elevated dihydroxyadenine levels in the urine. Dihydroxyadenine precipitates in renal parenchyma and becomes extremely insoluble in urine, forming crystals that can accumulate, grow, and form stones. This can lead to crystalline nephropathy.

Diagnosis

Adenine phosphoribosyltransferase deficiency is diagnosed based on the identification of dihydroxyadenine by kidney stone analysis or examination of crystals in the urine. The combination of infrared spectroscopy and morphologic examination under a stereomicroscope allows for the identification of dihydroxyadenine in all cases of kidney stones and should be analyzed whenever one becomes available. Biochemical stone analysis is unreliable for diagnosing APRT deficiency and is unable to distinguish dihydroxyadenine from uric acid. For the identification of dihydroxyadenine crystals, light and polarizing microscopy examination of crystalluria is a very helpful, noninvasive, and reasonably priced method. The most concentrated urine samples come from morning urine voids, which are ideal for studying crystalluria. One way to quantify something is to count the number of crystals per volume unit, which is higher in patients who are not receiving treatment.

References

References

1. (September 26, 2019). "Adenine Phosphoribosyltransferase Deficiency". University of Washington, Seattle.
2. (October 1, 2012). "Adenine phosphoribosyltransferase deficiency: MedlinePlus Genetics".
3. (July 1, 2014). "Adenine phosphoribosyltransferase (APRT) deficiency: identification of a novel nonsense mutation". Springer Science and Business Media LLC.
4. (2010). "Phenotype and Genotype Characterization of Adenine Phosphoribosyltransferase Deficiency". Ovid Technologies (Wolters Kluwer Health).
5. (November 1, 1987). "Human adenine phosphoribosyltransferase. Identification of allelic mutations at the nucleotide level as a cause of complete deficiency of the enzyme.". American Society for Clinical Investigation.
6. (March 1, 1988). "Human adenine phosphoribosyltransferase deficiency. Demonstration of a single mutant allele common to the Japanese.". American Society for Clinical Investigation.
7. Bollée, Guillaume. (2014). "Adenine phosphoribosyltransferase deficiency: Leave no stone unturned". Baishideng Publishing Group Inc..
8. (January 3, 2012). "Adenine phosphoribosyltransferase deficiency in children". Springer Science and Business Media LLC.
9. (1993). "Gout, uric acid and purine metabolism in paediatric nephrology". Springer Science and Business Media LLC.
10. (2012). "Adenine Phosphoribosyltransferase Deficiency". Ovid Technologies (Wolters Kluwer Health).
11. (1987). "Genetic and clinical studies on 19 families with adenine phosphoribosyltransferase deficiencies". Springer Science and Business Media LLC.
12. (2014). "Recurrent 2,8-Dihydroxyadenine Nephropathy: A Rare but Preventable Cause of Renal Allograft Failure". Elsevier BV.
13. (January 11, 2010). "Crystalline nephropathy due to 2,8-dihydroxyadeninuria: an under-recognized cause of irreversible renal failure". Oxford University Press (OUP).
14. (1985). "Common characteristics of mutant adenine phosphoribosyltransferases from four separate Japanese families with 2,8-dihydroxyadenine urolithiasis associated with partial enzyme deficiencies". Springer Science and Business Media LLC.
15. (2001). "Clinical features and genotype of adenine phosphoribosyltransferase deficiency in Iceland". Elsevier BV.
16. (1974). "Advances in Experimental Medicine and Biology". Springer US.
17. (2009). "Adenine Phosphoribosyltransferase Deficiency in a Chinese Man with Early-onset Gout". The Journal of Rheumatology.
18. "Autosomal recessive: MedlinePlus Medical Encyclopedia".
19. (1993). "Analysis of germline and in vivo somatic mutations in the human adenine phosphoribosyltransferase gene: Mutational hot spots at the intron 4 splice donor site and at codon 87". Elsevier BV.
20. (2005). "Aprt/Opn double knockout mice: Osteopontin is a modifier of kidney stone disease severity". Elsevier BV.
21. (1984). "Advances in Experimental Medicine and Biology". Springer US.
22. (October 23, 2018). "APRT deficiency: the need for early diagnosis". BMJ.
23. (1980). "Plasma concentration and renal excretion of adenine and 2,8-dihydroxyadenine after administration of adenine in man". Informa UK Limited.
24. (July 21, 1977). "Complete Deficiency of Adenine Phosphoribosyltransferase". Massachusetts Medical Society.
25. (1988). "2,8-Dihydroxyadeninuria: Laboratory Diagnosis and Therapy Control". S. Karger AG.
26. (October 19, 2004). "Clinical Value of Crystalluria and Quantitative Morphoconstitutional Analysis of Urinary Calculi". S. Karger AG.